ES2162913T3 - Preparado farmaceutico que contiene activadores de plasminogeno. - Google Patents

Preparado farmaceutico que contiene activadores de plasminogeno.

Info

Publication number
ES2162913T3
ES2162913T3 ES95910500T ES95910500T ES2162913T3 ES 2162913 T3 ES2162913 T3 ES 2162913T3 ES 95910500 T ES95910500 T ES 95910500T ES 95910500 T ES95910500 T ES 95910500T ES 2162913 T3 ES2162913 T3 ES 2162913T3
Authority
ES
Spain
Prior art keywords
pct
plasminogen activators
pharmaceutical preparation
preparation containing
containing plasminogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95910500T
Other languages
English (en)
Inventor
Ulrich Kohnert
Stephan Fischer
Hans-Jorg Markl
Heinrich Woog
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Application granted granted Critical
Publication of ES2162913T3 publication Critical patent/ES2162913T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION TRATA DE PREPARADOS FARMACEUTICOS QUE CONTIENEN ACTIVADORES DEL PLASMINOGENO, AZUCAR Y ACIDO TRANEXAMICO COMO UN LIOFILIZADO O UNA SOLUCION PARA INYECTAR O INFUNDIR. LOS PREPARADOS CONTIENEN EN PARTICULAR UN AZUCAR, UN AMORTIGUADOR DE FOSFATO, ACIDO TRANEXAMICO Y UN TENSIOACTIVO, Y LAS SOLUCIONES LIQUIDAS TIENEN PREFERIBLEMENTE UN PH DE 5,5-6,5.
ES95910500T 1994-02-21 1995-02-18 Preparado farmaceutico que contiene activadores de plasminogeno. Expired - Lifetime ES2162913T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4405426A DE4405426A1 (de) 1994-02-21 1994-02-21 Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate

Publications (1)

Publication Number Publication Date
ES2162913T3 true ES2162913T3 (es) 2002-01-16

Family

ID=6510724

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95910500T Expired - Lifetime ES2162913T3 (es) 1994-02-21 1995-02-18 Preparado farmaceutico que contiene activadores de plasminogeno.

Country Status (26)

Country Link
US (1) US5747030A (es)
EP (1) EP0746334B1 (es)
JP (1) JP3868997B2 (es)
KR (1) KR100356934B1 (es)
CN (1) CN1170591C (es)
AT (1) ATE205091T1 (es)
AU (1) AU691881B2 (es)
BR (1) BR9506840A (es)
CA (1) CA2183755C (es)
CZ (1) CZ286682B6 (es)
DE (2) DE4405426A1 (es)
DK (1) DK0746334T3 (es)
ES (1) ES2162913T3 (es)
FI (1) FI117925B (es)
HU (1) HU219769B (es)
MX (1) MX9603515A (es)
NO (1) NO317726B1 (es)
NZ (1) NZ281607A (es)
PL (1) PL181257B1 (es)
PT (1) PT746334E (es)
RU (1) RU2155067C2 (es)
SG (1) SG50567A1 (es)
SK (1) SK282827B6 (es)
TW (1) TW337997B (es)
WO (1) WO1995022347A1 (es)
ZA (1) ZA951371B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
US6653062B1 (en) * 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US20090214644A1 (en) * 2003-07-31 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20050245614A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
BRPI0622256A2 (pt) * 2005-12-20 2011-08-09 Bristol-Myers Squibb Company formulações estáveis adequadas para administração subcutánea compreendendo moléculas de ctla4ig
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
TWI788044B (zh) 2013-03-15 2022-12-21 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
MA39779A (fr) 2014-03-24 2017-02-01 Biogen Ma Inc Formulations de facteur ix lyophilisées
US11666532B2 (en) * 2018-01-19 2023-06-06 Hyloris Developments Sa Tranexamic acid oral solution
US10980757B2 (en) * 2018-09-06 2021-04-20 RTU Pharma SA Ready-to-use tranexamic acid intravenous solution
CA3185927A1 (en) * 2020-08-10 2022-02-17 Ray Anthony Mina ANOVER Tissue plasminogen activator formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3718889A1 (de) * 1987-06-05 1988-12-22 Behringwerke Ag Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
DE3942144A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von k1k2p pro

Also Published As

Publication number Publication date
PL315978A1 (en) 1996-12-23
SK107996A3 (en) 1997-04-09
WO1995022347A1 (de) 1995-08-24
CA2183755C (en) 2004-02-17
KR970701059A (ko) 1997-03-17
JP3868997B2 (ja) 2007-01-17
DE4405426A1 (de) 1995-08-24
AU691881B2 (en) 1998-05-28
AU1758195A (en) 1995-09-04
JPH09511495A (ja) 1997-11-18
ZA951371B (en) 1996-08-20
NZ281607A (en) 1997-04-24
NO317726B1 (no) 2004-12-13
FI963251A0 (fi) 1996-08-20
CN1170591C (zh) 2004-10-13
CZ243196A3 (en) 1997-01-15
FI963251A (fi) 1996-08-20
SG50567A1 (en) 1998-07-20
HU9602284D0 (en) 1996-10-28
ATE205091T1 (de) 2001-09-15
FI117925B (fi) 2007-04-30
HU219769B (hu) 2001-07-30
PL181257B1 (pl) 2001-06-29
PT746334E (pt) 2002-02-28
EP0746334A1 (de) 1996-12-11
CA2183755A1 (en) 1995-08-24
BR9506840A (pt) 1997-10-14
DK0746334T3 (da) 2001-12-27
CZ286682B6 (en) 2000-06-14
NO963460L (no) 1996-10-18
HUT74843A (en) 1997-02-28
EP0746334B1 (de) 2001-09-05
US5747030A (en) 1998-05-05
MX9603515A (es) 1997-03-29
SK282827B6 (sk) 2002-12-03
KR100356934B1 (ko) 2003-02-26
DE59509580D1 (de) 2001-10-11
NO963460D0 (no) 1996-08-20
TW337997B (en) 1998-08-11
CN1141592A (zh) 1997-01-29
RU2155067C2 (ru) 2000-08-27

Similar Documents

Publication Publication Date Title
ES2162913T3 (es) Preparado farmaceutico que contiene activadores de plasminogeno.
ATE146360T1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
NO883926D0 (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
KR950703987A (ko) G-csf의 안정한 동결건조된 약제학적 제제(stable lyophilized pharma ceutical preparations g-csf)
AU5795586A (en) Sterilant compositions
SE9502769D0 (sv) Bag for containing a sterile medical solution and method of mixing a sterile medecal solution
AU1446388A (en) Preparation of serine-n, n-diacetic acid and derivatives as complexing agents and detergents containing same
ATE151115T1 (de) Desinfektion von wässerigen lösungen
SE9300105D0 (sv) Stable protein solution
HUT67321A (en) Transdermal preparations containing lanolin derivatives as penetration- promoting agent
ES2132430T3 (es) Derivados de la quinolonilcarboxamidocefalosporina y composiciones farmaceuticas que los contienen.
ATE205399T1 (de) Eine lagerstabile wässrige lösung zur infusion die einen thrombininhibitor enthält
NO20003888L (no) Anti-enzympreparater omfattende etylendiamindiravsyre
CA2153787A1 (en) Solution containing igf-1
MX9704388A (es) Incremento de la concentracion de creatina y glicogeno en musculos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 746334

Country of ref document: ES